文献速递睡眠呼吸障碍

口腔矫治器对中重度阻塞性睡眠呼吸暂停严重程度、生活质量及生物标志物的影响

Impact of an oral appliance on obstructive sleep apnea severity, quality of life, and biomarkers.
PubMed 文献 · Laryngoscope · 2017-11-20

这项病例对照研究纳入呼吸暂停低通气指数(AHI)≥15次/小时的阻塞性睡眠呼吸暂停(OSA)患者,比较接受下颌前移装置(MAD)治疗者(30例)与拒绝治疗者(10例)在基线和6个月时的多导睡眠监测、生活质量量表及炎症标志物。结果显示,MAD可显著改善AHI、最低血氧饱和度、部分睡眠分期、嗜睡评分、生活质量总分及部分炎症指标,在部分中重度患者中可作为拒绝持续气道正压通气(CPAP)者的替代治疗。

要点

  • MAD可显著改善中重度OSA患者的AHI和最低血氧饱和度。
  • MAD可改善嗜睡和生活质量,并降低部分炎症标志物水平。
  • 对拒绝CPAP的中重度OSA患者,MAD可能是可行的替代治疗。

核心结论

  • MAD可显著改善多导睡眠监测参数、生活质量和部分炎症标志物(CRP、IL-1β、TNF-α),在相当比例的中度OSA患者和部分重度OSA患者中有效。
  • 对于拒绝CPAP的中重度OSA患者,MAD可能是可行的替代治疗。

研究设计与样本

  • 病例对照研究;研究组为仅接受MAD治疗、AHI≥15次/小时的患者(n=30),对照组为拒绝任何治疗的患者(n=10)。
  • 在基线和6个月时评估多导睡眠监测、Epworth嗜睡量表(ESS)、睡眠功能结局问卷(FOSQ)、C反应蛋白(CRP)、白细胞介素1β、白细胞介素6和肿瘤坏死因子α(TNF-α)。

主要发现

  • 基线时研究组快速眼动睡眠比例和CRP水平高于对照组(P<.05)。
  • 6个月时,与未治疗组相比,MAD显著改善AHI和最低血氧饱和度(P<.01),改善非快速眼动(N)1期和N3期睡眠(P<.05)。
  • 6个月时MAD显著改善ESS评分(P<.05)、FOSQ总分(P<.01)、白细胞介素1β(P<.05)和TNF-α(P<.01)。

关键数值与推荐

  • 总体、中度和重度OSA组分别有63.3%、75%和50%达到至少良好反应。
  • 研究纳入标准为AHI≥15次/小时。
  • 证据等级为3b。

临床怎么用

  • 对拒绝CPAP的中重度OSA患者,可考虑MAD作为替代治疗,并随访睡眠参数、生活质量和炎症标志物。

局限性

  • 对照组样本量较小(n=10),研究设计为病例对照研究,证据等级为3b。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE/HYPOTHESIS: To investigate outcomes including efficacy, quality of life, and levels of inflammatory markers of a mandibular advancement device (MAD) for moderate-to-severe obstructive sleep apnea (OSA). STUDY DESIGN: Case-control study. METHODS: Patients with apnea-hypopnea index (AHI) ≥ 15/hr who only accepted MAD therapy (study group) or who refused any treatment (control group) were recruited. At baseline and at 6 months, polysomnography, Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire (FOSQ), C-reactive protein (CRP), interleukin 1β, interleukin 6, and tumor necrosis factor α (TNF-α) were assessed in both groups. RESULTS: At baseline, the study group (n = 30) showed a higher percentage of rapid eye movement sleep and higher CRP levels (P < .05) than the control group (n = 10). At 6 months, the MAD significantly improved AHI and lowest oxygen saturation (P < .01), non-rapid eye movement (N)1 and N3 sleep stages (P < .05), ESS score (P < .05), FOSQ total score (P < .01), interleukin 1β (P < .05), and TNF-α (P < .01) compared with the untreated group. In the overall, moderate, and severe OSA groups, 63.3%, 75%, and 50%, respectively, achieved at least good response. CONCLUSIONS: Use of a MAD significantly improved polysomnographic parameters, quality of life, and some inflammatory markers (CRP, IL-β, and TNF-α) in a significant proportion of patients with moderate OSA and in some patients with severe OSA. Hence, a MAD may be a viable alternative therapy in patients with moderate-to-severe OSA who refuse continuous positive airway pressure. LEVEL OF EVIDENCE: 3b. Laryngoscope, 128:1720-1726, 2018.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Fernández-Julián E, Pérez-Carbonell T, Marco R, et al. Impact of an oral appliance on obstructive sleep apnea severity, quality of life, and biomarkers. Laryngoscope. 2017. PMID: 29152745. doi:10.1002/lary.26913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。